Document:

Exhibit
10.1

 

SECURITIES
PURCHASE AGREEMENT

 

This
SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of Novemer 26, 2021, by and between PROPANC BIOPHARMA,
INC., a Delaware corporation, with its address at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the “Company”),
and SIXTH STREET LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal Road, Suite 623, Alexandria,
VA 22314 (the “Buyer”).

 

WHEREAS:

 

A.
The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded
by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the
Securities Act of 1933, as amended (the “1933 Act”); and

 

B.
Buyer desires to purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement a convertible
note of the Company, in the form attached hereto as Exhibit A, in the aggregate principal amount of $53,750.00 (together with any note(s)
issued in replacement thereof or as a dividend thereon or otherwise with respect thereto in accordance with the terms thereof, the “Note”),
convertible into shares of common stock, $0.001 par value per share, of the Company (the “Common Stock”), upon the terms
and subject to the limitations and conditions set forth in such Note.

 

NOW
THEREFORE, the Company and the Buyer severally (and not jointly) hereby agree as follows:

 

1.
Purchase and Sale of Note.

 

a.
Purchase of Note. On the Closing Date (as defined below), the Company shall issue and sell to the Buyer and the Buyer agrees to
purchase from the Company such principal amount of Note as is set forth immediately below the Buyer’s name on the signature pages
hereto.

 

b.
Form of Payment. On the Closing Date (as defined below), (i) the Buyer shall pay the purchase price for the Note to be issued
and sold to it at the Closing (as defined below) (the “Purchase Price”) by wire transfer of immediately available funds to
the Company, in accordance with the Company’s written wiring instructions, against delivery of the Note in the principal amount
equal to the Purchase Price as is set forth immediately below the Buyer’s name on the signature pages hereto, and (ii) the Company
shall deliver such duly executed Note on behalf of the Company, to the Buyer, against delivery of such Purchase Price.

 

c.
Closing Date. Subject to the satisfaction (or written waiver) of the conditions thereto set forth in Section 6 and Section 7 below,
the date and time of the issuance and sale of the Note pursuant to this Agreement (the “Closing Date”) shall be 12:00 noon,
Eastern Standard Time on or about November 29, 2021, or such other mutually agreed upon time. The closing of the transactions contemplated
by this Agreement (the “Closing”) shall occur on the Closing Date at such location as may be agreed to by the parties.

 

    	 

     

    

 

2.
Buyer’s Representations and Warranties. The Buyer represents and warrants to the Company that:

 

a.
Investment Purpose. As of the date hereof, the Buyer is purchasing the Note and the shares of Common Stock issuable upon conversion
of or otherwise pursuant to the Note (such shares of Common Stock being collectively referred to herein as the “Conversion Shares”
and, collectively with the Note, the “Securities”) for its own account and not with a present view towards the public sale
or distribution thereof, except pursuant to sales registered or exempted from registration under the 1933 Act.

 

b.
Accredited Investor Status. The Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation
D (an “Accredited Investor”).

 

c.
Reliance on Exemptions. The Buyer understands that the Securities are being offered and sold to it in reliance upon specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying upon the truth
and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and understandings
of the Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of the Buyer to acquire the
Securities.

 

d.
Information. The Company has not disclosed to the Buyer any material nonpublic information and will not disclose such information
unless such information is disclosed to the public prior to or promptly following such disclosure to the Buyer.

 

e.
Legends. The Buyer understands that the Note and, until such time as the Conversion Shares have been registered under the 1933
Act; or may be sold pursuant to an applicable exemption from registration, the Conversion Shares may bear a restrictive legend in substantially
the following form:

 

“THE
SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR UNDER ANY STATE SECURITIES LAWS, AND MAY NOT BE PLEDGED, SOLD, ASSIGNED, HYPOTHECATED OR OTHERWISE TRANSFERRED UNLESS
(1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR (2)
THE ISSUER OF SUCH SECURITIES RECEIVES AN OPINION OF COUNSEL TO THE HOLDER OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE REASONABLY
ACCEPTABLE TO THE ISSUER, THAT SUCH SECURITIES MAY BE PLEDGED, SOLD, ASSIGNED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS.”

 

The
legend set forth above shall be removed and the Company shall issue a certificate without such legend to the holder of any Security upon
which it is stamped, if, unless otherwise required by applicable state securities laws, (a) such Security is registered for sale under
an effective registration statement filed under the 1933 Act or otherwise may be sold pursuant to an exemption from registration without
any restriction as to the number of securities as of a particular date that can then be immediately sold, or (b) such holder provides
the Company with an opinion of counsel, in form, substance and scope customary for opinions of counsel in comparable transactions, to
the effect that a public sale or transfer of such Security may be made without registration under the 1933 Act, which opinion shall be
accepted by the Company so that the sale or transfer is effected. The Buyer agrees to sell all Securities, including those represented
by a certificate(s) from which the legend has been removed, in compliance with applicable prospectus delivery requirements, if any. In
the event that the Company does not accept the opinion of counsel, which opinion is in such satisfactory form, substance and scope as
described above, provided by the Buyer with respect to the transfer of Securities pursuant to an exemption from registration, such as
Rule 144, at the Deadline (as defined in the Note), it will be considered an Event of Default pursuant to Section 3.2 of the Note.

 

    	2

     

    

 

f.
Authorization; Enforcement. This Agreement has been duly and validly authorized by the Buyer. This Agreement has been duly executed
and delivered on behalf of the Buyer, and this Agreement constitutes a valid and binding agreement of the Buyer enforceable in accordance
with its terms.

 

3.
Representations and Warranties of the Company. The Company represents and warrants to the Buyer that:

 

a.
Organization and Qualification. The Company and each of its Subsidiaries (as defined below), if any, is a corporation duly organized,
validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority (corporate
and other) to own, lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated
and conducted , except for those jurisdictions in which failure to have such authority would not have a Material Adverse Effect. “Subsidiaries”
means any corporation or other organization, whether incorporated or unincorporated, in which the Company owns, directly or indirectly,
any equity or other ownership interest.

 

b.
Authorization; Enforcement. (i) The Company has all requisite corporate power and authority to enter into and perform this Agreement,
the Note and to consummate the transactions contemplated hereby and thereby and to issue the Securities, in accordance with the terms
hereof and thereof, (ii) the execution and delivery of this Agreement, the Note by the Company and the consummation by it of the transactions
contemplated hereby and thereby (including without limitation, the issuance of the Note and the issuance and reservation for issuance
of the Conversion Shares issuable upon conversion or exercise thereof) have been duly authorized by the Company’s Board of Directors
and no further consent or authorization of the Company, its Board of Directors, or its shareholders is required, (iii) this Agreement
has been duly executed and delivered by the Company by its authorized representative, and such authorized representative is the true
and official representative with authority to sign this Agreement and the other documents executed in connection herewith and bind the
Company accordingly, and (iv) this Agreement constitutes, and upon execution and delivery by the Company of the Note, each of such instruments
will constitute, a legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms ,
except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’
rights generally and general principles of equity.

 

c.
Capitalization. As of September 30, 2021, the authorized common stock of the Company consists of 1,000,000,000
authorized shares of Common Stock, $0.001 par value per share, of which 49862220 shares are issued and outstanding. All of such
outstanding shares of capital stock are, or upon issuance will be, duly authorized, validly issued, fully paid and non-assessable.

 

    	3

     

    

 

d.
Issuance of Shares. The Conversion Shares are duly authorized and reserved for issuance and, upon conversion of the Note in accordance
with its respective terms, will be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims and encumbrances
with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Company
and will not impose personal liability upon the holder thereof.

 

e.
No Conflicts. The execution, delivery and performance of this Agreement, the Note by the Company and the consummation by the Company
of the transactions contemplated hereby and thereby (including, without limitation, the issuance and reservation for issuance of the
Conversion Shares) will not (i) conflict with or result in a violation of any provision of the Company’s Certificate of Incorporation
or By-laws, or (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default (or an event which with
notice or lapse of time or both could become a default) under, or give to others any rights of termination, amendment, acceleration or
cancellation of, any agreement, indenture, patent, patent license or instrument to which the Company or any of its Subsidiaries is a
party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities
laws and regulations and regulations of any self-regulatory organizations to which the Company or its securities are subject) applicable
to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected
(except for such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would not, individually
or in the aggregate, have a Material Adverse Effect). The businesses of the Company and its Subsidiaries, if any, are not being conducted,
and shall not be conducted so long as the Buyer owns any of the Securities, in violation of any law, ordinance or regulation of any governmental
entity, except for such violations as would not, individually or in the aggregate, have a Material Adverse Effect. “Material Adverse
Effect” means any material adverse effect on the business, operations, assets or financial condition of the Company or its Subsidiaries,
if any, taken as a whole, or on the transactions contemplated hereby or by the agreements or instruments to be entered into in connection
herewith.

 

f.
SEC Documents; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by it with the SEC pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “1934
Act”) (all of the foregoing filed prior to the date hereof and all exhibits included therein and financial statements and schedules
thereto and documents (other than exhibits to such documents) incorporated by reference therein, being hereinafter referred to herein
as the “SEC Documents”). Upon written request the Company will deliver to the Buyer true and complete copies of the SEC Documents,
except for such exhibits and incorporated documents or such SEC Documents which are available on EDGAR. As of their respective dates
or if amended, as of the dates of the amendments, the SEC Documents complied in all material respects with the requirements of the 1934
Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents, at
the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required
to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made,
not misleading. None of the statements made in any such SEC Documents is, or has been, required to be amended or updated under applicable
law (except for such statements as have been amended or updated in subsequent filings prior the date hereof). As of their respective
dates or if amended, as of the dates of the amendments, the financial statements of the Company included in the SEC Documents complied
as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect
thereto. Such financial statements have been prepared in accordance with United States generally accepted accounting principles, consistently
applied, during the periods involved and fairly present in all material respects the consolidated financial position of the Company and
its consolidated Subsidiaries as of the dates thereof and the consolidated results of their operations and cash flows for the periods
then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). The Company is subject to the reporting
requirements of the 1934 Act.

 

    	4

     

    

 

g.
Absence of Certain Changes. Except as set forth in the SEC Documents, since September 30, 2021, except as may have been advised
by the Company to the Buyer, there has been no material adverse change and no material adverse development in the assets, liabilities,
business, properties, operations, financial condition, results of operations, prospects or 1934 Act reporting status of the Company or
any of its Subsidiaries.

 

h.
Absence of Litigation. Except as set forth in the SEC Documents, there is no action, suit, claim, proceeding, inquiry or investigation
before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company
or any of its Subsidiaries, threatened against or affecting the Company or any of its Subsidiaries, or their officers or directors in
their capacity as such, that could have a Material Adverse Effect. The Company and its Subsidiaries are unaware of any facts or circumstances
which might give rise to any of the foregoing that could have a Material Adverse Effect.

 

i.
No Integrated Offering. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly
or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances that would require
registration under the 1933 Act of the issuance of the Securities to the Buyer. The issuance of the Securities to the Buyer will not
be integrated with any other issuance of the Company’s securities (past, current or future) for purposes of any shareholder approval
provisions applicable to the Company or its securities.

 

j.
No Brokers. The Company has taken no action which would give rise to any claim by any person for brokerage commissions, transaction
fees or similar payments relating to this Agreement or the transactions contemplated hereby.

 

k.
No Investment Company. The Company is not, and upon the issuance and sale of the Securities as contemplated by this Agreement
will not be an “investment company” required to be registered under the Investment Company Act of 1940 (an “Investment
Company”). The Company is not controlled by an Investment Company.

 

l.
Breach of Representations and Warranties by the Company. If the Company breaches any of the representations or warranties set
forth in this Section 3, and such breach continues for a period of ten (10) days after written notice thereof to the Borrower from the
Holder, in addition to any other remedies available to the Buyer pursuant to this Agreement, it will be considered an Event of default
under Section 3.4 of the Note.

 

4.
COVENANTS.

 

a.
Best Efforts. The Company shall use its best efforts to satisfy timely each of the conditions described in Section 7 of this Agreement.

 

    	5

     

    

 

b.
Form D; Blue Sky Laws. The Company agrees to timely make any filings required by federal and state laws as a result of the closing
of the transactions contemplated by this Agreement to the extent any such filings are required by federal and state laws.

 

c.
Use of Proceeds. The Company shall use the proceeds for general working capital purposes.

 

d.
Expenses. At the Closing, the Company’s obligation with respect to the transactions contemplated by this Agreement is to
reimburse Buyer’ expenses shall be $3,750.00 for Buyer’s legal fees and due diligence fee.

 

e.
Corporate Existence. So long as the Buyer beneficially owns any Note, the Company shall maintain its corporate existence and shall
not sell all or substantially all of the Company’s assets which would render the Company a “shell company” as such
term is defined in Rule 144 of the Securities Act, except with the prior written consent of the Buyer.

 

f.
Breach of Covenants. If the Company breaches any of the covenants set forth in this Section 4, and such breach continues for a
period of ten (10) days after written notice thereof to the Borrower from the Holder, in addition to any other remedies available to
the Buyer pursuant to this Agreement, it will be considered an event of default under Section 3.4 of the Note.

 

g.
Failure to Comply with the 1934 Act. So long as the Buyer beneficially owns the Note, the Company shall comply with the reporting
requirements of the 1934 Act; and the Company shall continue to be subject to the reporting requirements of the 1934 Act.

 

h.
Trading Activities. Neither the Buyer nor its affiliates has an open short position in the common stock of the Company and the
Buyer agrees that it shall not, and that it will cause its affiliates not to, engage in any short sales of or hedging transactions with
respect to the common stock of the Company.

 

i.
The Buyer is Not a “Dealer”. The Buyer and the Company hereby acknowledge and agree that the Buyer has not: (i) acted
as an underwriter; (ii) acted as a market maker or specialist; (iii) acted as “de facto” market maker; or (iv) conducted
any other professional market activities such as providing investment advice, extending credit and lending securities in connection;
and thus that the Buyer is not a “Dealer” as such term is defined in the 1934 Act.

 

    	6

     

    

 

5.
Transfer Agent Instructions. The Company shall issue irrevocable instructions to its transfer agent to issue certificates, registered
in the name of the Buyer or its nominee, for the Conversion Shares in such amounts as specified from time to time by the Buyer to the
Company upon conversion of the Note in accordance with the terms thereof (the “Irrevocable Transfer Agent Instructions”).
In the event that the Company proposes to replace its transfer agent, the Company shall provide, within five (5) business days prior
to the effective date of such replacement, a fully executed Irrevocable Transfer Agent Instructions in a form as initially delivered
pursuant to this Agreement (including but not limited to the provision to irrevocably reserve shares of Common Stock in the Reserved
Amount as such term is defined in the Note) signed by the successor transfer agent to Company and the Company. Prior to registration
of the Conversion Shares under the 1933 Act or the date on which the Conversion Shares may be sold pursuant to an exemption from registration,
all such certificates shall bear the restrictive legend specified in Section 2(e) of this Agreement. The Company warrants that: (i) no
instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 5, will be given by the Company to its
transfer agent and that the Securities shall otherwise be freely transferable on the books and records of the Company as and to the extent
provided in this Agreement and the Note; (ii) it will not direct its transfer agent not to transfer or delay, impair, and/or hinder its
transfer agent in transferring (or issuing)(electronically or in certificated form) any certificate for Conversion Shares to be issued
to the Buyer upon conversion of or otherwise pursuant to the Note as and when required by the Note and this Agreement; and (iii) it will
not fail to remove (or directs its transfer agent not to remove or impairs, delays, and/or hinders its transfer agent from removing)
any restrictive legend (or to withdraw any stop transfer instructions in respect thereof) on any certificate for any Conversion Shares
issued to the Buyer upon conversion of or otherwise pursuant to the Note as and when required by the Note and/or this Agreement. If the
Buyer provides the Company and the Company’s transfer, at the cost of the Buyer, with an opinion of counsel in form, substance
and scope customary for opinions in comparable transactions, to the effect that a public sale or transfer of such Securities may be made
without registration under the 1933 Act, the Company shall permit the transfer, and, in the case of the Conversion Shares, promptly instruct
its transfer agent to issue one or more certificates, free from restrictive legend, in such name and in such denominations as specified
by the Buyer. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Buyer, by
vitiating the intent and purpose of the transactions contemplated hereby. Accordingly, the Company acknowledges that the remedy at law
for a breach of its obligations under this Section 5 may be inadequate and agrees, in the event of a breach or threatened breach by the
Company of the provisions of this Section, that the Buyer shall be entitled, in addition to all other available remedies, to an injunction
restraining any breach and requiring immediate transfer, without the necessity of showing economic loss and without any bond or other
security being required.

 

6.
Conditions to the Company’s Obligation to Sell. The obligation of the Company hereunder to issue and sell the Note to the
Buyer at the Closing is subject to the satisfaction, at or before the Closing Date of each of the following conditions thereto, provided
that these conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion:

 

a.
The Buyer shall have executed this Agreement and delivered the same to the Company.

 

b.
The Buyer shall have delivered the Purchase Price in accordance with Section 1(b) above.

 

c.
The representations and warranties of the Buyer shall be true and correct in all material respects as of the date when made and as of
the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date), and the Buyer
shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this
Agreement to be performed, satisfied or complied with by the Buyer at or prior to the Closing Date.

 

d.
No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority
over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.

 

    	7

     

    

 

7.
Conditions to The Buyer’s Obligation to Purchase. The obligation of the Buyer hereunder to purchase the Note at the Closing
is subject to the satisfaction, at or before the Closing Date of each of the following conditions, provided that these conditions are
for the Buyer’s sole benefit and may be waived by the Buyer at any time in its sole discretion:

 

a.
The Company shall have executed this Agreement and delivered the same to the Buyer.

 

b.
The Company shall have delivered to the Buyer the duly executed Note (in such denominations as the Buyer shall request) in accordance
with Section 1(b) above.

 

c.
The Irrevocable Transfer Agent Instructions, in form and substance reasonably satisfactory to the Buyer, shall have been delivered to
and acknowledged in writing by the Company’s Transfer Agent.

 

d.
The representations and warranties of the Company shall be true and correct in all material respects as of the date when made and as
of the Closing Date as though made at such time (except for representations and warranties that speak as of a specific date) and the
Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required
by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date. The Buyer shall have received
a certificate or certificates, executed by the chief executive officer of the Company, dated as of the Closing Date, to the foregoing
effect and as to such other matters as may be reasonably requested by the Buyer including, but not limited to certificates with respect
to the Board of Directors’ resolutions relating to the transactions contemplated hereby.

 

e.
No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority
over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.

 

f.
No event shall have occurred which could reasonably be expected to have a Material Adverse Effect on the Company including but not limited
to a change in the 1934 Act reporting status of the Company or the failure of the Company to be timely in its 1934 Act reporting obligations.

 

g.
The Conversion Shares shall have been authorized for quotation on an exchange or electronic quotation system and trading in the Common
Stock on such exchange or electronic quotation system shall not have been suspended by the SEC or an exchange or electronic quotation
system.

 

8.
Governing Law; Miscellaneous.

 

a.
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Virginia without
regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated
by this Agreement shall be brought only in the state courts of Virginia or in the federal courts located in the state and city of Alexandria.
The parties to this Agreement hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and
shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. The Company and Buyer
waive trial by jury. The Buyer shall be entitled to recover from the Company its reasonable attorney’s fees and costs. In the event
that any provision of this Agreement or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable
statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed
modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall
not affect the validity or enforceability of any other provision of any agreement. Each party hereby irrevocably waives personal service
of process and consents to process being served in any suit, action or proceeding in connection with this Agreement, the Note or any
related document or agreement by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law.

 

    	8

     

    

 

b.
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of
which shall constitute one and the same agreement and shall become effective when counterparts have been signed by each party and delivered
to the other party.

 

c.
Headings. The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation
of, this Agreement.

 

d.
Severability. In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule
of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to
conform with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect
the validity or enforceability of any other provision hereof.

 

e.
Entire Agreement; Amendments. This Agreement and the instruments referenced herein contain the entire understanding of the parties
with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor
the Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this Agreement may
be waived or amended other than by an instrument in writing signed by the majority in interest of the Buyer.

 

f.
Notices. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be
in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified,
return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted
by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified most
recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a)
upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address
or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the
first business day following such delivery (if delivered other than on a business day during normal business hours where such notice
is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed
to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be
as set forth in the heading of this Agreement and with respect to the Buyer, with a copy by fax only to (which copy shall not constitute
notice) to Naidich Wurman LLP, 111 Great Neck Road, Suite 214, Great Neck, NY 11021, Attn: Allison Naidich, facsimile: 516-466-3555,
e-mail: allison@nwlaw.com, and with respect to the Company, with a copy to (which copy shall not constitute notice) to Patrizio
& O’Leary LLP, 300 Carnegie Center, Suite 150, Princeton, NJ 08540, Attn: John O’Leary, Esq., e-mail: joleary@po-legal.com.
Each party shall provide notice to the other party of any change in address.

 

    	9

     

    

 

g.
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
assigns. Neither the Company nor the Buyer shall assign this Agreement or any rights or obligations hereunder without the prior written
consent of the other. Notwithstanding the foregoing, the Buyer may assign its rights hereunder to any person that purchases Securities
in a private transaction from the Buyer or to any of its “affiliates,” as that term is defined under the 1934 Act, without
the consent of the Company.

 

h.
Survival. The representations and warranties of the Company and the agreements and covenants set forth in this Agreement shall
survive the closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of the Buyer. The Company agrees
to indemnify and hold harmless the Buyer and all their officers, directors, employees and agents for loss or damage arising as a result
of or related to any breach or alleged breach by the Company of any of its representations, warranties and covenants set forth in this
Agreement or any of its covenants and obligations under this Agreement, including advancement of expenses as they are incurred.

 

i.
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and
shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

j.
No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

 

k.
Remedies. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Buyer by
vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Company acknowledges that the remedy at law
for a breach of its obligations under this Agreement will be inadequate and agrees, in the event of a breach or threatened breach by
the Company of the provisions of this Agreement, that the Buyer shall be entitled, in addition to all other available remedies at law
or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any
breach of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity of showing economic loss
and without any bond or other security being required.

 

[THE
REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

 

    	10

     

    

 

IN
WITNESS WHEREOF, the undersigned Buyer and the Company have caused this Agreement to be duly executed as of the date first above written.

 

PROPANC
BIOPHARMA, INC.

 

	By:	/s/
    James Nathanielsz	 
	Name:
    	James
    Nathanielsz	 
	Title:
    	Chief
    Executive Officer	 

 

SIXTH
STREET LENDING LLC

 

	By:
    	/s/
    Curt Kramer	 
	Name:
    	Curt
    Kramer	 
	Title:
    	President	 

 

AGGREGATE
SUBSCRIPTION AMOUNT:

 

	Aggregate
    Principal Amount of Note:	$53,750.00
	 	 
	Aggregate
    Purchase Price: 	$53,750.00

 

    	11EX-4.8

 Exhibit 4.8 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of July 7, 2021, by and among (i) Alpha Tau
Medical Ltd., an Israeli private company (the “Company”), (ii) the entities and individuals identified in Schedule 1 attached hereto (collectively, the “Key Holders”), (iii) each of the entities and individuals identified
in Schedule 2 hereto (the “Series A Holders”), (iv) each of the entities and individuals identified in Schedule 3 hereto (the “Series B Holders”), and (v) shareholders who have become a party hereto from time
to time with the consent of the Company upon execution of the Joinder set forth in Annex A hereto, and whose names have been or will be added to an updated version of Schedule 4 (together with the Key Holders, the Series A Holders and
the Series B Holders, the “Investor(s)”). 
 RECITALS 

WHEREAS, the Investors hold Company’s Ordinary Shares, Series A Preferred Shares and Series B Preferred Shares; 

WHEREAS, the Company and certain of the Investors and the Key Holders are parties to that certain Amended Investors’ Rights Agreement dated as of
April 16, 2020 (the “Prior Agreement”), and desire to amend, restate and terminate the Prior Agreement in its entirety and to accept the rights and obligations created pursuant to this Agreement, in lieu of the rights and
obligations granted to them under the Prior Agreement; and 
 WHEREAS, under that certain Agreement and Plan of Merger, dated as of July 7, 2021 (the
“Merger Agreement”), by and among the Company, Archery Merger Sub, Inc., the Company’s wholly-owned subsidiary (“Merger Sub”), and Healthcare Capital Corp. (“HCCC”), pursuant to which
Merger Sub will merge with and into HCCC (the “Merger”), with HCCC surviving as a wholly-owned subsidiary of the Company, and which will result in the Ordinary Shares (as defined below), being registered under Section 12(b) of
the 1934 Act (as defined below) and listed on Nasdaq Stock Market, Healthcare Capital Sponsor LLC (the “Sponsor”) will be issued Ordinary Shares and, upon and subject to the closing of the Merger, will become an Investor that is a
party hereto by executing a joinder agreement, in the form attached to this Agreement as Annex A. 
 NOW, THEREFORE, the parties hereby agree
as follows: 
 1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is
controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or more
general partners or managing members of, or shares the same management company with, such Person. The term “control” as used herein 

shall mean the holding of the majority of the shares of such party, or the power to appoint the majority of the directors of such party or the power to direct
the management and policies of such party, through contractual means or otherwise. 
 1.2 “Amended AOA” means the
Company’s Amended and Restated Articles of Association, as may be lawfully amended from time to time in accordance with its terms and applicable law. 

 1.3 “Damages” means any loss, damage, claim or liability (joint or several)
to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any
untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an
omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents
or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.4 “Eligible Investor” means any (i) Series B Holder who acquired at least 1.5% of the Series B Preferred Shares issued
under the Series B Securities Purchase Agreement (as defined below); and (ii) Series A Holders who acquired at least 1.5% of the Series A Preferred Shares under the Series A Securities Purchase Agreement (as defined below), and (iii) Key
Holder for so long as it continues to hold at least 3% of the Company’s as-converted and fully-diluted share capital until the earlier of: (i) Company’s notice pursuant to Section 2.2; or
(ii) until the first Demand Notice date. 
 1.5 “Exchange Act” means the Securities Exchange Act of 1934, as amended,
and the rules and regulations promulgated thereunder. 
 1.6 “Form F-1” means such
form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.7 “Form F-3” means such form under the Securities Act as in effect on the date
hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed or to be filed in the future by the Company with the SEC. 

1.8 “IFRS” means International Financial Reporting Standards. 

1.9 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.10 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement. 

1.11 “Investor Majority” means Holders which hold more than 50% of the Registrable Securities then outstanding, and in all
events include, prior to the IPO, the Lead A Investor (as defined in the Amended AOA). 
 1.12 “IPO” means the
Company’s first underwritten public offering of its Ordinary Shares under the Securities Act, or, alternatively, a SPAC Transaction. 

1.13 “Merger” has the meaning provided in the Recitals hereto. 

1.14 “Ordinary Shares” means, the Ordinary Shares of the Company, with no par value. 

1.15 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

  
 2 

 1.16 “Ordinary Registrable Securities” means (i) any Ordinary Shares
currently held by the Key Holders, (ii) any Ordinary Shares, or any Ordinary Shares issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company acquired by Key Holders after the date hereof
pursuant to options and/or rights to acquire additional Ordinary Shares which are in existence at the closing of the Company’s IPO; and (iii) any Ordinary Shares issued as (or issuable upon the conversion or exercise of any warrant, right,
or other security that is issued as) a dividend, upon any stock split or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above. 

1.17 “Preferred Registrable Securities” means (i) the Ordinary Shares issuable or issued upon conversion of the Series A
Preferred Shares, including but not limited to the Warrant Shares; (ii) the Ordinary Shares issuable or issued upon conversion of the Series B Preferred Shares; (iii) any Ordinary Shares, or any Ordinary Shares issued or issuable (directly or
indirectly) upon conversion and/or exercise of any other securities of the Company acquired after the date hereof by (a) Series A Holders, including but not limited to the Warrant Shares or (b) the Series B Holders; and (iv) any
Ordinary Shares issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend, upon any stock split or other distribution with respect to, or in exchange for or in replacement of, the
shares referenced in clauses (i), (ii) and (iii) above. 
 1.18 “Registrable Securities” means the Ordinary Registrable
Securities, the Preferred Registrable Securities and the Ordinary Shares issuable to the Sponsor upon consummation of the transactions under the Merger Agreement. Registrable Securities shall not include any (a) Ordinary Shares which have
previously been registered, (b) Ordinary Shares which have previously been sold to the public, or (c) any Ordinary Shares eligible for resale pursuant to SEC Rule 144 with no volume limitation. 

1.19 “Registrable Securities then outstanding”, or similar term, means the number of shares determined by adding the number of
outstanding Ordinary Shares that are Registrable Securities and the number of Ordinary Shares issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

1.20 “SEC” means the Securities and Exchange Commission. 

1.21 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.22 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.23 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. 

1.24 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale
of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection 2.6. 

1.25 “Series A Preferred Shares” means the Company’s Series A Preferred Shares, no par value per share. 

1.26 “Series B Preferred Shares” means the Company’s Series B Preferred Shares, no par value per share. 

  
 3 

 1.27 “Series A Securities Purchase Agreement” means the Securities Purchase
Agreement by and between the Company and the Series A Holders, dated as of September 2, 2018. 
 1.28 “Series B
Securities Purchase Agreement” means the Securities Purchase Agreement by and between the Company and the Series B Holders, dated as of April 6, 2020. 

1.29 “SPAC Transaction” means a merger (including the Merger), consolidation, share exchange, share purchase or other business
combination between (1) the shareholders of the Company, the Company and/or a subsidiary of the Company and (2) a publicly listed “special purpose acquisition company” (a “SPAC”) and/or its shareholders (or a
subsidiary of the publicly listed company), in connection with which either (x) the Company becomes a publicly listed Company (or a subsidiary of a publicly listed company) with Shares registered under Section 12(b) of the 1934 Act, or
(y) the shareholders of the Company immediately prior to the closing of such merger, consolidation, share exchange, share purchase or other business combination hold or have the right, by virtue of their shareholdings in the Company, to acquire
or to be issued, immediately following the closing of such merger, consolidation, share exchange, share purchase or other business combination, the majority shareholding in a publicly listed company that is the surviving entity of such merger,
consolidation, share exchange, share purchase or other business combination. 
 1.30 “Preferred Shares” means either Series
A Preferred Shares and/or Series B Preferred Shares. 
 1.31 “Warrant Shares” means the Series A Preferred Shares issued or
issuable upon exercise of the warrants granted by the Company to certain of the Series A Holders (the “Warrants”), as detailed on the Capitalization Table attached as Schedule 3.3(a)(iv) to the Series A Securities Purchase
Agreement, as such Warrants have been amended and the numbers amended as may be adjusted thereunder, under the Amended AOA and/or under the Warrants, and shall include the Ordinary Shares into which such Warrant Shares may be convertible at any
time. 
 2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form F-1 Demand. If at any time during the time period commencing immediately following one
hundred eighty (180) days after the effective date of the registration statement for the IPO (or earlier upon expiration or waiver of any lockup applicable to such Holders party hereto), with respect to an IPO which is not a SPAC Transaction,
or following the closing of the Merger Agreement and expiration or waiver of any lockup applicable to such Holders party hereto, with respect to an IPO which is a SPAC Transaction, and in all cases ending five (5) years thereafter, the Company
receives a written request from the Investor Majority that the Company file a Form F-1 registration statement covering at a minimum the public sale of Preferred Registrable Securities having an estimated
aggregate public offering price (net of underwriting discounts and commissions) of at least five million dollars (US$5,000,000), then the Company shall (x) within fourteen (14) days after the date such request is given, give notice thereof
(the “Demand Notice”) to all Holders other than the Initiating Holders, and (y) as soon as practicable, and in any event within ninety (90) days after the date such request is given by the Initiating Holders, file a Form F-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in
such registration by any other Holder, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c), 2.1(d)
and 2.3. 

  
 4 

 (b) Form F-3 Demand. If at any time when it
is eligible to use a Form F-3 registration statement, the Company receives a request from the Investor Majority that the Company file a Form F-3 registration
statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least US$2 million, then the Company shall (i) within fourteen (14) days after
the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating
Holders, file a Form F-3 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities
requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within fifteen (15) days of the date the Demand Notice is given, and in each case, subject to the limitations of
Subsections 2.1(c), 2.1(d) and 2.3. 
 (c) Notwithstanding the foregoing obligations, if the Company furnishes
to Holders requesting a registration pursuant to this Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially
detrimental to the Company and its shareholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would
(i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide
business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and
any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than one hundred and twenty (120) days after the request of the Initiating Holders is given; provided,
however, that the Company may not invoke this right more than twice in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other shareholder
during such 120-day period. 
 (d) The Company shall not be obligated to effect, or to take any
action to effect, any registration pursuant to Subsection 2.1(a): (i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred and eighty
(180) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith best efforts to cause such registration statement to become effective; (ii) after the Company
has effected two (2) registrations; or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities, all of which may be immediately registered on Form F-3 pursuant to a
request made pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) if the Company has effected two (2) registrations pursuant
to Subsection 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as the
applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit, pursuant to Subsection
2.6, their right to one demand registration statement, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d). 

2.2 Company Registration. If the Company proposes to register (including, for this purpose, any registration effected by
the Company for any shareholder(s)) any of its Ordinary Shares under the Securities Act in connection with the public offering of such securities, the Company shall, at such time, promptly give each Holder notice of such registration. Upon the
request of the Investor Majority holding Registrable Securities having an estimated aggregate public offering price (net of underwriting discounts and commissions) of at least one million dollars 

  
 5 

 
(US$1,000,000) given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Subsection 2.3, cause to be registered all of the
Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Subsection 2.2 before the effective date of such
registration, whether or not any Holder has elected to include Registrable Securities in such registration; the expenses of such withdrawn registration shall be borne by the Company in accordance with Subsection 2.6. 

2.3 Underwriting Requirements. 

(a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be of international repute and
selected by the Initiating Holders, subject to the reasonable approval of the Company. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with
the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection 2.3, if the managing
underwriter advises the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Company shall so advise all Holders of Registrable Securities that otherwise would be underwritten
pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be reduced as required by the underwriter and allocated as follows: first, Preferred Registrable Securities held by the Initiating
Holders (pro rata to the respective number of Registrable Securities required by the Initiating Holders to be included in this registration); second, to the extent possible, Preferred Registrable Securities held by the non-Initiating Holders (pro rata to the respective number of Registrable Securities required by such Investors to be included in this registration); and third, to the extent possible, Ordinary Registrable
Securities (pro rata to the respective number of Registrable Securities then held by the Holders participating in such Registration); provided, however, that in any event all Registrable Securities must be included in such registration
prior to any other shares of the Company or its shareholders of shares which are not “Registrable Securities” under this Agreement. 

(b) In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Subsection 2.2
(Company Registration), the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its
underwriters, and then only in such quantity as the underwriters in their reasonable discretion determine will not jeopardize the success of the offering by the Company. If the underwriters determine that less than all of the Registrable Securities
requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated as follows: first, all the securities to be included by the Company; second, such number
of Preferred Registrable Securities (which shall be allocated among all Holders thereof requesting to be included in the registration and underwriting in proportion, as nearly as practicable, to the respective amounts of Preferred Registrable
Securities held by them at the time of filing the registration statement), requested to be registered by Holders thereof; and third, such number of Ordinary Registrable Securities (which shall be allocated among all Holders requesting to be
included in the registration and underwriting in proportion, as nearly as practicable, to the respective amounts of Ordinary Registrable Securities held by them at the time of filing the registration statement), requested to be registered by such
Holders. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are 

  
 6 

 first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the
offering be reduced below fifty percent (50%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination
described above and no other shareholders’ securities are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, any selling Holder’s holdings shall be aggregated with the
holdings of its Permitted Transferees, which shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities
owned by all Persons included in such “selling Holder,” as defined in this sentence. 
 (c) For purposes of Subsection 2.1,
a registration shall not be counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Subsection 2.3(a), fewer than fifty percent (50%) of the total number of Registrable Securities that
Holders have requested to be included in such registration statement are actually included. 
 (d) Subsection 2.1 2.2 shall not
apply to any registration statement on Form F-1 or F-4 to be filed by the Company in connection with a SPAC Transaction (including any resale registration statements
amendments thereto required to be filed by the Company in connection with any financing related to the SPAC Transaction). 

2.4 Obligations of the Company. Whenever required under this Section 2 to effect the registration of any
Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) prepare and file with the SEC a registration
statement with respect to such Registrable Securities and use its best efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such
registration statement effective for a period of up to ninety (90) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such ninety
(90) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter, from selling any securities included in such registration, and (ii) in the case of any registration of
Registrable Securities on Form F-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be
extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold and/or may be sold under Rule 144; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with
such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its best efforts to register and qualify the securities covered by such registration statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent to service of
process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

  
 7 

 (e) in the event of any underwritten public offering, enter into and perform its obligations
under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement; 

(f) use its best efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities
exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for
all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) furnish, at the request of any
Holder requesting registration of Registrable Securities pursuant to Section 2, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to Section 2, if such
securities are being sold through underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective, (i) an opinion, dated such date, of
the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting
registration of Registrable Securities, and (ii) a letter dated such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to
underwriters in an underwritten public offering (to the extent deliverable in accordance with their professional standards), addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities; notify each
selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed, or the
happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to
make the statements therein not misleading in the light of the circumstances then existing; and 
 (i) after such registration statement
becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant
to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of
disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations,
filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and
disbursements of one counsel for the selling Holders which, subject to the Company’s prior approval, shall be selected by the Investor Majority (“Selling Holder Counsel”), shall be borne and paid by the Company;
provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the
Investor Majority (in which case all selling Holders shall bear such expenses pro rata based upon 

  
 8 

 the number of Registrable Securities that were to be included in the withdrawn
registration), unless the Investor Majority agree to forfeit their right to one registration pursuant to Subsection 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have
learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information,
then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to registration pursuant to Subsection 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant
to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise
delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder,
and the partners officers, directors, and shareholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such
Holder or underwriter within the meaning of the Securities Act or the Exchange Act, or the equivalent securities exchange law of another jurisdiction (collectively, “Holder’s Indemnitees”), against any Damages, and the Company
will pay to each such Holder’s Indemnitee any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred;
provided, however, that the indemnity agreement contained in this Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company,
which consent shall not be unreasonably withheld or delayed, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information
furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration, and, provided, further, that the foregoing indemnity obligations are subject
to the condition that, insofar as it relates to any untrue statement or omission (or alleged untrue statement or omission) made in the preliminary prospectus but eliminated or remedied in the amended prospectus on file with the SEC at the time the
registration statement becomes effective or in the final prospectus filed with the SEC, such indemnity agreement shall not inure to the benefit of the Holder’s Indemnitees, if a copy of the amended or final prospectus was furnished, either by
way of filing with or furnishing to the SEC or otherwise, to the Person asserting the loss, liability, suit, claim or damage at or prior to the time such furnishing is required by any applicable securities law and such that the amended or final
prospectus would have cured the defect giving rise to such loss, liability, suit, claim or damage. 
 (b) To the extent permitted by law,
each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the
meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter
or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling
Holder expressly for use in connection 

  
 9 

 with such registration; and each such selling Holder will pay to the Company and each other aforementioned
Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity
agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld or
delayed; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such
Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 
 (c) Promptly
after receipt by an indemnified party under this Subsection 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a
claim in respect thereof is to be made against any indemnifying party under this Subsection 2.8, give the indemnifying party a written notice of the commencement thereof. The indemnifying party shall have the right to participate in such
action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided,
however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the
indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by
such counsel in such action. The failure to give a written notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this
Subsection 2.8, only to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure to give a written notice to the indemnifying party will not relieve it of any liability that
it may have to any indemnified party otherwise than under this Subsection 2.8. No indemnifying party will consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the
claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. 
 (d) To provide for
just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but
it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case,
notwithstanding the fact that this Subsection 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this
Subsection 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, or liabilities to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect
the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant
equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or
alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement
or omission; provided, however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder
pursuant to such registration statement, 

  
 10 

 and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Subsection
2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the
case of willful misconduct or fraud by such Holder. 
 (e) Unless otherwise superseded by an underwriting agreement entered into in
connection with the underwritten public offering, the obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section
2, and otherwise shall survive the termination of this Agreement. 
 2.9 Reports Under Exchange Act. With a view
to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on
Form F-3, the Company shall 
 (a) make and keep available adequate current public information, as
those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b) file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act
(at any time after the Company has become subject to such reporting requirements); and 
 (c) furnish to any Holder, so long as the Holder
owns any Registrable Securities, forthwith upon written request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after it has become subject to such
reporting requirements), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form F-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such
securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form F-3 (at any time after the Company so qualifies to
use such form). 
 2.10 Limitations on Subsequent Registration Rights. From and after the date of this Agreement and until the closing
of the IPO, the Company shall not, without the prior consent of the Investor Majority (except in the context of the sale of the type of Senior Shares which in accordance with Article 11(d)(iv) of the Amended AOA are not subject to a Preferred Shares
Majority (as such terms are defined in the Amended AOA)), enter into any agreement with any holder or prospective holder of any securities of the Company that would (i) allow such holder or prospective holder to include such securities in any
registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable
Securities of the Holders that are included; or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder, or otherwise grant such holder senior registration
rights. 

  
 11 

 2.11 “Market Stand-off” Agreement.
Each Holder hereby agrees that such Holder shall not, without the prior written consent of the managing underwriter (or, in the case of an IPO that is a SPAC Transaction, the prior written consent of the Company), sell or otherwise transfer or
dispose of any securities of the Company held by such Holder (other than those included in the registration) for a period specified by the underwriters of Ordinary Shares (or other securities) of the Company (or, in the case of an IPO that is a SPAC
Transaction, for a period specified by the Company) not to exceed (a) one hundred and eighty (180) days from the date of the final prospectus relating to the IPO, or in the case of an IPO Offering that is a SPAC Transaction, the date of
the consummation of the SPAC Transaction in connection with the IPO and (b) ninety (90) days from the date of the final prospectus filed by the Company in connection with any other offering; notwithstanding the foregoing, however, any agreement
consummated in connection with a SPAC Transaction that stipulates a longer lock-up period shall govern; and further provided that: 

(a) all officers and directors of the Company, all shareholders of the Company holding at least 1% of the outstanding share capital and holders
of registration rights enter into similar agreements; and 
 (b) any discretionary waiver, release or termination of the foregoing
restriction shall apply to all holders of share capital of the Company, on a pro rata basis. 
 The foregoing provisions of this
Subsection 2.11: (1) shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any Permitted Transferee of the Holder, provided that the Permitted Transferee
agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value and (2) shall not be construed as to prohibit or limit the exercise of warrants or
options during such period. The underwriters in connection with such registration are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they
were parties hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary to give
further effect thereto. 
 2.12 Foreign Jurisdiction. If, upon the consent of the Investor Majority, the IPO, or any other
registration of Company shares, is effected in a jurisdiction other than the United States, the provisions hereof shall apply in respect thereto, and to the laws of such jurisdiction, mutatis mutandis. 

2.13 Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any
registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earlier of (i) the closing of a Deemed Liquidation, as such term is defined in the Amended AOA, so long as, on the consummation of such Deemed Liquidation,
(A) with respect to Series A Holders, each of the Series A Holders receives no less than the Series A Preference (as defined in the Amended AOA) for each Series A Preferred Share then held by it, in cash or other equally-liquid proceeds;
and (B) with respect to Series B Holders, each of the Series B Holders receives no less than the Series B Preference (as defined in the Amended AOA) for each Series B Preferred Share then held by it, in cash or other equally-liquid
proceeds; (ii) such time as SEC Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares without limitation during a three-month period without registration; and
(iii) the 5th anniversary of the date which is 180 days following the IPO. 

3. Information Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Investor: 

  
 12 

 (a) as soon as practicable, but in any event within one hundred and twenty (120) days after
the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and the comparable amounts for the prior year, with an explanation of any material
differences between such amounts and a schedule as to the sources and applications of funds for such year, and (iii) a statement of shareholders’ equity as of the end of such year; with all such financial statements (i)-(iii) to be audited
and certified by independent public accountants of internationally-recognized standing selected by the Company; 
 (b) as soon as
practicable, but in any event within sixty (60) days after the end of each of the first three (3) quarters of each fiscal year of the Company (beginning with the first quarter of 2019), unaudited but reviewed statements of income and cash
flows for such fiscal quarter, and an unaudited balance sheet and a statement of shareholders’ equity as of the end of such fiscal quarter, all prepared in accordance with US GAAP or IFRS (except that such financial statements may
(i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with US GAAP or IFRS); 

(c) together with the reports detailed in Subsections 3.1(a) and 3.1(b) above, a statement showing the number of shares of each class and
series of share capital and securities convertible into or exercisable for share capital outstanding at the end of the period, the Ordinary Shares issuable upon conversion or exercise of any outstanding securities convertible or exercisable for
Ordinary Shares and the exchange ratio or exercise price applicable thereto, and the number of options (issued and not yet issued but reserved for issuance, if any), all in sufficient detail as to permit the Investors to calculate their respective
percentage equity ownership in the Company, and certified by the chief financial officer or chief executive officer of the Company as being true, complete, and correct; 

(d) with respect to the financial statements called for in Subsection 3.1(a) and Subsection 3.1(b), an instrument executed by the
chief financial officer and chief executive officer of the Company certifying that such financial statements were prepared in accordance with IFRS consistently applied with prior practice for earlier periods (except as otherwise set forth in
Subsection 3.1(b)) and fairly present the financial condition of the Company and its results of operation for the periods specified therein, unless similar certifications are included in the accountant’s opinion or review report, as the
case may be, relating to such financial statements; and 
 (e) such other information relating to the financial condition, business,
prospects, or corporate affairs of the Company as any Eligible Investor may from time to time reasonably request. 
 If, for any period, the
Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated (i.e. consolidating financial
statements of the Company and all such consolidated subsidiaries). 
 3.2 Inspection. The Company shall permit, each
Eligible Investor, at such party’s expense and not more than twice in 12 months, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with
its officers, during normal business hours of the Company as may be reasonably requested by the Eligible Investor. 

  
 13 

 3.3 Limitations on Information Rights. The Company may refrain from providing a
particular portion of the information pursuant to Sections 3.1 and 3.2 to a Series A Holder or Series B Holder if the Board reasonably and in good faith determines that (i) such portion of the information is a Company trade secret or involves
personal information; or (ii) the disclosure of such information would be reasonably expected to adversely affect the attorney-client privilege between the Company and its counsel, and provided that this Section 3.3 shall not limit the
Company’s obligations to provide any information required under Sections 3.1 and/or 3.2 which does not fall within the limitations set forth in this Section 3.3. 

3.4 Termination of Covenants. The covenants set forth in Subsection 3.1 and Subsection 3.2 shall terminate and be of no further force or
effect upon the closing of the Company’s IPO, 
 which imposes an obligation on the Company to provide periodic reports. 

3.5 Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any
purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement, unless such confidential information (a) is known or becomes known to the public in
general (other than as a result of a breach of this Subsection 3.5 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made
known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys,
accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor,
if such prospective purchaser agrees to be bound by the provisions of this Subsection 3.5 with the Company being a beneficiary of such obligation; (iii) to any existing or prospective Affiliate, provided that such Investor informs such Person
that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure, and
takes reasonable steps to minimize the extent of any such required disclosure. 
 4. Miscellaneous. 

4.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a
transferee of Registrable Securities that (i) is a Permitted Transferee (as defined in the Amended AOA) of a Holder; or (ii) after such transfer, holds at least the lowest of: (a) 1,000,000 shares (subject to appropriate adjustment for
stock splits, stock dividends, combinations, and other recapitalizations), (b) 50% of the Registrable Securities held by the transferor immediately prior thereto but in any event more than 300,000 shares and (c) in the case of a Series A Holder
or Series B Holder only, 50% of the Registrable Securities held by the transferor at the Closing (in each case (a)-(c), subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided,
however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and
(y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Subsection 2.1110. The terms and conditions of this Agreement
inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective
successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

  
 14 

 4.2 Governing Law. This Agreement shall be exclusively governed and construed in
accordance with the laws of the State of Israel, without regard to conflicts of laws provisions thereof. 
 4.3
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

4.4 Titles and Subtitles. The titles of the sections and subsections of this Agreement are for convenience of reference
only and are not to be considered in construing this Agreement. 
 4.5 Notices. All notices required or permitted
hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified; 
 (b) when
sent by facsimile or email, with confirmation of transmission if sent during normal business hours of the recipient, if not, then on the next business day; (c) ten (10) days after having been sent by registered or certified mail, return receipt
requested, postage prepaid; or (d) two business days after deposit with an internationally-recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent out as set forth in
the Purchase Agreement, or to the addresses provided by a party hereunder. 
 4.6 Amendments and Waivers. Any term of
this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the Investor
Majority. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 

4.7 Severability. In the event one or more of the provisions of this Agreement should, for any reason, be held to be
invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions of this Agreement, which shall remain enforceable, to the fullest extent permitted by law. Furthermore, to the
fullest extent possible, the provisions of this Agreement (including, without limitation, the portion of this Agreement containing any provision held to be invalid, illegal or unenforceable that is not itself invalid, illegal or unenforceable) shall
be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable. 
 4.8
Aggregation of Shares. All Registrable Securities held or acquired by Permitted Transferees of a Holder shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Permitted
Transferees may apportion such rights as among themselves in any manner they deem appropriate. 
 4.9 Entire
Agreement. This Agreement (including any Schedules hereto) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject
matter hereof existing between the parties is expressly canceled. 
 4.10 Jurisdiction. The competent courts in Israel shall have sole
and exclusive jurisdiction over all matters relating to this Agreement. 

  
 15 

 4.11 Delays or Omissions. No delay or omission to exercise any right,
power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such non-breaching or non-defaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or
default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

[Remainder of Page Intentionally Left Blank] 

  
 16 

 [EXECUTION PAGE TO AMENDED INVESTORS’ RIGHTS AGREEMENT] 

IN WITNESS WHEREOF, the parties hereto have executed this Amended Investors’ Rights Agreement as of the date set forth in the first paragraph
hereof. 
  

							
	Alpha Tau Medical Ltd.	  	Medison Ventures Ltd.
				
	By (sign name):	 	 /s/ Uzi Sofer
	  	By (sign name):	  	 /s/ Meir Jakobsohn

	Print Name:	 	Uzi Sofer	  	Print Name:	  	Meir Jakobsohn
	Title:	 	CEO	  	Title:	  	CEO
	Date:	 	July 14, 2021	  	Date:	  	14/07/2021
		 		  		  	
		
	Edmund Shamsi	  	Mishor Tau LLC
				
	By (sign name):	 	 /s/ Edmund Shamsi
	  	By (sign name):	  	 /s/ Edmund Shamsi

	Print Name:	 	EDMUND SHAMSI	  	Print Name:	  	EDMUND SHAMSI
	Title:	 	General Manager	  	Title:	  	General Manager
	Date:	 	7/14/21	  	Date:	  	7/14/21
		
	OurCrowd (Investment in AlphaT) L.P.	  	OurCrowd 50 L.P.
				
	By (sign name):	 	 /s/ Josh Wolff Cali Chill
	  	By (sign name):	  	 /s/ Josh Wolff Cali Chill

	Print Name:	 	Josh Wolff Cali Chill	  	Print Name:	  	Josh Wolff Cali Chill
	Title:	 	COO CLO	  	Title:	  	COO CLO
	Date:	 	13 July 2021	  	Date:	  	13 July 2021
		
	OurCrowd General Partner L.P. or an affiliate as may be directed	  	OurCrowd International Investment III L.P.
				
	By (sign name):	 	 /s/ Josh Wolff Cali Chill
	  	By (sign name):	  	 /s/ Josh Wolff Cali Chill

	Print Name:	 	Josh Wolff Cali Chill	  	Print Name:	  	Josh Wolff Cali Chill
	Title:	 	COO CLO	  	Title:	  	COO CLO
	Date:	 	13 July 2021	  	Date:	  	13 July 2021

 [EXECUTION PAGE TO AMENDED INVESTORS’ RIGHTS AGREEMENT] 

IN WITNESS WHEREOF, the parties hereto have executed this Amended Investors’ Rights Agreement as of the date set forth in the first paragraph
hereof. 
  

							
	Shavit Capital Fund 4 (Israel), L.P.	  	Shavit Capital Fund IV (US), L.P.
		
	By: Shavit Capital Fund 4 GP, LP	  	By: Shavit Capital Fund 4 GP, LP
		
	By: Shavit Capital Management 4 (GP) Ltd., its	  	By: Shavit Capital Management 4 (GP) Ltd., its
	general partner:	  	general partner:
				
	By (sign name):	  	 /s/ Gary Leibler
	  	By (sign name):	  	 /s/ Gary Leibler

	Print Name:	  	Gary Leibler	  	Print Name:	  	Gary Leibler
	Title:	  	Managing Partner	  	Title:	  	Managing Partner
	Date:	  	13/07/2021	  	Date:	  	13/07/2021
		
	Shavit Capital Fund III (US), L.P.	  	Shavit Capital Fund 3 (Israel), L.P.
		
	By: Shavit Capital Fund 3 GP, LP	  	By: Shavit Capital Fund 3 GP, LP
		
	By: Shavit Capital Management 3 (GP) Ltd., its	  	By: Shavit Capital Management 3 (GP) Ltd., its
	general partner:	  	general partner:
				
	By (sign name):	  	 /s/ Gary Leibler
	  	By (sign name):	  	 /s/ Gary Leibler

	Print Name:	  	Gary Leibler	  	Print Name:	  	Gary Leibler
	Title:	  	Managing Partner	  	Title:	  	Managing Partner
	Date:	  	13/07/2021	  	Date:	  	13/07/2021

 ANNEX A 

Form of Joinder Agreement to 

AMENDED AND RESTATED SHAREHOLDERS RIGHTS AGREEMENT 

of 
 ALPHATAU MEDICAL LTD. 

This Joinder Agreement (this “Joinder”) is executed and delivered as of [ * ] in respect of that certain Amended and Restated Investors’
Rights Agreement, dated as of [*], 2021 by and among AlphaTau Medical Ltd., an Israeli company (the “Company”), (ii) the entities and individuals identified in Schedule 1 attached hereto (collectively, the “Key
Holders”), (iii) each of the entities and individuals identified in Schedule 2 hereto (the “Series A Holders”, and together with the Key Holders, the “Existing Investors”), (iv) each of the entities
and individuals identified in Schedule 3 hereto (the “Series B Holders”, and together with the Existing Investors, the “Investor(s)”) (the “A&R IRA”). Capitalized terms used but not defined
herein shall have the meaning ascribed to them in the A&R IRA. 
 By executing and delivering this Joinder with the Company, the undersigned hereby
joins and becomes a party to the A&R IRA with all of the rights and subject to all of the obligations of an “Investor” under the A&R IRA, and shall be added to Schedule 4 thereto and shall be considered an
“Investor” for all purposes of the A&R IRA. 
 IN WITNESS WHEREOF the parties have signed this Agreement as of the date first hereinabove set
forth. 
 By: _______________________ 
 Name of Investor:
___________________ 
 If Investor is an entity, title of Investor: _______________ 

ACCEPTED AND ACKNOWLEDGED: 
 AlphaTau Medical Ltd. 

By: ___________________________ 
 Name: 

Title: 

 SCHEDULE 1 

Key Holders 
  

	 	•	 	 Uzi Sofer 

	 	•	 	 Althera Medical Ltd. 

	 	•	 	 Medison Ventures Ltd. 

 SCHEDULE 2 

Series A Holders 
  

	 	•	 	 Shavit Capital Fund IV (US), L.P. 

	 	•	 	 Shavit Capital Fund 4 (Israel), L.P. 

	 	•	 	 Shavit Capital Fund III (US), L.P. 

 

	 	•	 	 Shavit Capital Fund 3 (Israel), L.P. 

 

	 	•	 	 OurCrowd (Investment in AlphaT) L.P. 

	 	•	 	 OurCrowd 50 L.P. 

  

	 	•	 	 OurCrowd International Investment III L.P. 

	 	•	 	 Edmund Shamsi 

  

	 	•	 	 Arie Jacobson 

  

	 	•	 	 Shmuel Rubinshtein 

	 	•	 	 Arie Kremer 

  

	 	•	 	 Thomas Schmidek 

	 	•	 	 Alex Sugar 

  

	 	•	 	 Abraham Hoffman and Miriam Hoffman 

	 	•	 	 Adi Schmidek Barer and Oded Barer 

 

	 	•	 	 Ofir Schmidek 

	 	•	 	 Sindy Schmidek 

  

	 	•	 	 Tamar Schmidek Arbel and Elad Arbel 

	 	•	 	 Maryana Vladimirski 

  

	 	•	 	 Beata Koch 

  

	 	•	 	 SRL TOLKO 

	 	•	 	 Ariel Tolub 

  

	 	•	 	 Gov Financial Holdings Ltd. 

	 	•	 	 Levy Stephane 

  

	 	•	 	 Gabriel Menaged 

  

	 	•	 	 VP Company Investment 2016, LLC 

	 	•	 	 Joshua Kiernan 

  

	 	•	 	 The Alan C. Agnes B Mendelson Family trust 

	 	•	 	 Stuart Kurlander 

  

	 	•	 	 Ehrlich François 

 

	 	•	 	 Patricof 2000 Family Trust 

	 	•	 	 Crescent Trust 

  

	 	•	 	 Richie Wolfe 

  

	 	•	 	 Matan Horovitz 

  

	 	•	 	 RR Investment 2012, LP 

	 	•	 	 Eldar Ben Ruby 

  

	 	•	 	 Clifford M.J Felig 

	 	•	 	 Dan Geva 

  

	 	•	 	 Harry Grynberg 

  

	 	•	 	 Anat Ann Cooper Ron 

	 	•	 	 Maayan Kashi 

	 	•	 	 Michael Tal 

	 	•	 	 Shay Bensky 

  

	 	•	 	 Benjamin Shamsi 

	 	•	 	 Maoz Leb 

  

	 	•	 	 Armando Carciente 

	 	•	 	 Elisha Zeiger 

  

	 	•	 	 Menachem Lamm 

	 	•	 	 Lior Ofir 

  

	 	•	 	 Adam Shames 

  

	 	•	 	 Jay (Yaacov) shames 

	 	•	 	 Lee Amir 

  

	 	•	 	 Ori Sela 

  

	 	•	 	 Yarden Manor 

	 	•	 	 Moria Ankry 

  

	 	•	 	 Rivka Levemberg 

	 	•	 	 Daniel Lavine 

  

	 	•	 	 HarrMich LLC 

  

	 	•	 	 Morry Blumenfeld 

	 	•	 	 Mimoun Rudy 

  

	 	•	 	 Yaacov Ginou 

  

	 	•	 	 Ariel, Natania and Eitan Feifel 

	 	•	 	 Anturio Holding S.A 

  

	 	•	 	 Stuart Mintz 

	 	•	 	 Lisa Deutsch 

	 	•	 	 Eran Benita 

	 	•	 	 Amnon Gat 

  

	 	•	 	 Shmuel David Adler 

	 	•	 	 Aron Tendler 

  

	 	•	 	 Volker Schewitz 

  

	 	•	 	 Rebecca Mintz Gecovich 

	 	•	 	 Csintalan Sandor 

  

	 	•	 	 S.P.C.M Ltd. 

  

	 	•	 	 Palo Alto Group Inc. 

  

	 	•	 	 Viking Maccabee holdings Ltd. 

	 	•	 	 Arc Group Ventures LLC 

 

	 	•	 	 Bernard Sammy Tolub 

	 	•	 	 Medison Ventures Ltd. 

	 	•	 	 Amit Yuval 

  

	 	•	 	 451we Alpha LLC 

	 	•	 	 Zohar Buchan 

  

	 	•	 	 Nurit Avruch 

  

	 	•	 	 Daphna Gishron 

 SCHEDULE 3 

Series B Holders 
  

	 	•	 	 Medison Ventures Ltd. 

  

	 	•	 	 Edmund Shamsi and/or affiliate as directed 

	 	•	 	 Pnina Shamsi 

  

	 	•	 	 Joshua Jacob Shamsi 

	 	•	 	 Mishor Tau LLC 

  

	 	•	 	 OurCrowd General Partner L.P. or an affiliate as may be directed 

 

	 	•	 	 Milch Investment Holdings II, LLC 

	 	•	 	 Chesapeake Advisory Group, LLC 

 

	 	•	 	 Issachar Knoll or an affiliate as may be directed 

	 	•	 	 Yehuda Laniado/Arie Boim/Avraham Moshe Margalit or an affiliate as may be directed 

	 	•	 	 Shavit Capital Fund IV (US), L.P. 

 

	 	•	 	 Shavit Capital Fund 4 (Israel), L.P. 

	 	•	 	 Intercambio Comercial SA de CV 

	 	•	 	 Elmrock Capital 

  

	 	•	 	 Aryeh Levine 

	 	•	 	 Rina Mazooz 

	 	•	 	 Roei Shunim 

  

	 	•	 	 Thomas Schmidek 

  

	 	•	 	 Abraham Hoffman and Miriam Hoffman 

	 	•	 	 Adi Schmidek Barer and Oded Barer 

 

	 	•	 	 Ofir Schmidek 

	 	•	 	 Sindy Schmidek 

  

	 	•	 	 Tamar Schmidek Arbel and Elad Arbel 

	 	•	 	 Vladimirsky Marianna 

  

	 	•	 	 Beata Koch 

  

	 	•	 	 RR Investment 2012, LP 

	 	•	 	 Daniel Lavine 

  

	 	•	 	 Morry Blumenfeld 

	 	•	 	 Elliot Eisenberg 

	 	•	 	 Red Red Inc. 

  

	 	•	 	 Joshua Kiernan 

  

	 	•	 	 The Alan C.& Agnes B.Mendelson Family Trust 

	 	•	 	 Stuart Kurlander 

  

	 	•	 	 VP Company Investment 2018, LLC 

	 	•	 	 Clifford M.J Felig 

  

	 	•	 	 Anat Ann Cooper Ron 

  

	 	•	 	 Arc Group Ventures LLC 

	 	•	 	 HarrMich LLC 

  

	 	•	 	 Arie Kramer 

	 	•	 	 Aron Tendler 

  

	 	•	 	 Bangkok Bank Public Company Limited

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}]]